This comprehensive review examines the impact of hydrogel spacers on rectal dosimetry and toxicity in prostate cancer radiotherapy.
Evidence indicates that hydrogel spacers are safe and result in minimal peri-operative morbidity. They significantly reduce rectal morbidity, as supported by several Phase II and III clinical trials and subsequent meta-analysis.
While hydrogel spacers show promise in reducing rectal toxicity, further research is needed to explore their role in prostate stereotactic beam radiotherapy and post-radiotherapy local recurrence.
Current data on sexual function and oncological outcomes remain limited, but ongoing studies aim to provide further insights into the benefits of hydrogel spacers in managing prostate cancer.
